Aarey Drugs & Pharmaceuticals Limited has announced its unaudited financial results for the third quarter ended December 31, 2025. The Board of Directors approved these results in a meeting held on February 11, 2026, alongside a limited review report. The company reported a decline in its quarterly revenue compared to both the previous quarter and the same period last year. For the quarter ended December 31, 2025, revenue from operations stood at ₹96.43 Crores, representing a decline of approximately 27.9% compared to the ₹133.79 Crores reported in the corresponding quarter of the previous year. On a quarter-on-quarter (QoQ) basis, revenue decreased by roughly 10.8% from ₹108.10 Crores in the preceding quarter. Despite the revenue dip, the company remained profitable with a net profit of ₹1.02 Crores for the quarter, which is a significant increase from the ₹0.47 Crores reported in the previous quarter, although it reflects a year-on-year (YoY) decline from the previous year’s performance in certain metrics.

Aarey Drugs & Pharmaceuticals Limited, established in 1990 and based in Thane, Maharashtra, is a prominent manufacturer of Active Pharmaceutical Ingredients (APIs), bulk drugs, and specialty chemicals. The company’s product portfolio includes Methyl Nitro Imidazole, Metronidazole, and Metronidazole Benzoate, catering to diverse industrial applications and pharmaceutical formulation manufacturers globally. In addition to manufacturing, the firm is a significant importer and distributor of industrial solvents and chemicals across India. Managed by the Ghatalia family, the company operates a manufacturing unit at MIDC Tarapur and maintains a strong presence in the trading of chemical products. Recent corporate updates in 2025 highlight a strategic shift in ownership, with promoter holding decreasing from 44.80% in September 2025 to 39.05% by December 2025. Notable investors include the India Opportunities Growth Fund Ltd – Pinewood Strategy, which holds approximately 1.75% to 2.34% of the company’s shares as a leading public institutional shareholder.